Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

moxifloxacin hydrochloride

×

Overview

What is These highlights do not include all the information needed to use VIGAMOX® Solution safely and effectively. See full prescribing information for VIGAMOX® Solution.VIGAMOX® (moxifloxacin hydrochloride ophthalmic solution) 0.5% as baseSterile topical ophthalmic solutionInitial U.S. Approval 1999?

VIGAMOX® (moxifloxacin hydrochloride ophthalmic solution) 0.5% is a sterile solution for topical ophthalmic use. Moxifloxacin hydrochloride is an 8-methoxy fluoroquinolone anti-infective, with a diazabicyclononyl ring at the C7 position.

Chemical Name:1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolol[3,4-b]pyridin-6-yl]-4-oxo-3-quinoline carboxylic acid, monohydrochloride. Moxifloxacin hydrochloride is a slightly yellow to yellow crystalline powder. Each mL of VIGAMOX® solution contains 5.45 mg moxifloxacin hydrochloride, equivalent to 5 mg moxifloxacin base.

Contains: Active:

Inactives:

VIGAMOX® solution is an isotonic solution with an osmolality of approximately 290 mOsm/kg.



What does These highlights do not include all the information needed to use VIGAMOX® Solution safely and effectively. See full prescribing information for VIGAMOX® Solution.VIGAMOX® (moxifloxacin hydrochloride ophthalmic solution) 0.5% as baseSterile topical ophthalmic solutionInitial U.S. Approval 1999 look like?



What are the available doses of These highlights do not include all the information needed to use VIGAMOX® Solution safely and effectively. See full prescribing information for VIGAMOX® Solution.VIGAMOX® (moxifloxacin hydrochloride ophthalmic solution) 0.5% as baseSterile topical ophthalmic solutionInitial U.S. Approval 1999?

4 mL bottle filled with 3 mL sterile ophthalmic solution of moxifloxacin hydrochloride, 0.5% as base. ()

What should I talk to my health care provider before I take These highlights do not include all the information needed to use VIGAMOX® Solution safely and effectively. See full prescribing information for VIGAMOX® Solution.VIGAMOX® (moxifloxacin hydrochloride ophthalmic solution) 0.5% as baseSterile topical ophthalmic solutionInitial U.S. Approval 1999?

How should I use These highlights do not include all the information needed to use VIGAMOX® Solution safely and effectively. See full prescribing information for VIGAMOX® Solution.VIGAMOX® (moxifloxacin hydrochloride ophthalmic solution) 0.5% as baseSterile topical ophthalmic solutionInitial U.S. Approval 1999?

VIGAMOX® solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms:

Corynebacterium

Micrococcus luteus*

Staphylococcus aureus

Staphylococcus epidermidis

Staphylococcus haemolyticus

Staphylococcus hominis

Staphylococcus warneri*

Streptococcus pneumoniae

Streptococcus viridans

Acinetobacter lwoffii*

Haemophilus influenzae

Haemophilus parainfluenzae*

Chlamydia trachomatis

*Efficacy for this organism was studied in fewer than 10 infections.

Instill one drop in the affected eye 3 times a day for 7 days.


What interacts with These highlights do not include all the information needed to use VIGAMOX® Solution safely and effectively. See full prescribing information for VIGAMOX® Solution.VIGAMOX® (moxifloxacin hydrochloride ophthalmic solution) 0.5% as baseSterile topical ophthalmic solutionInitial U.S. Approval 1999?

Sorry No Records found


What are the warnings of These highlights do not include all the information needed to use VIGAMOX® Solution safely and effectively. See full prescribing information for VIGAMOX® Solution.VIGAMOX® (moxifloxacin hydrochloride ophthalmic solution) 0.5% as baseSterile topical ophthalmic solutionInitial U.S. Approval 1999?

Sorry No Records found


What are the precautions of These highlights do not include all the information needed to use VIGAMOX® Solution safely and effectively. See full prescribing information for VIGAMOX® Solution.VIGAMOX® (moxifloxacin hydrochloride ophthalmic solution) 0.5% as baseSterile topical ophthalmic solutionInitial U.S. Approval 1999?

Sorry No Records found


What are the side effects of These highlights do not include all the information needed to use VIGAMOX® Solution safely and effectively. See full prescribing information for VIGAMOX® Solution.VIGAMOX® (moxifloxacin hydrochloride ophthalmic solution) 0.5% as baseSterile topical ophthalmic solutionInitial U.S. Approval 1999?

Sorry No records found


What should I look out for while using These highlights do not include all the information needed to use VIGAMOX® Solution safely and effectively. See full prescribing information for VIGAMOX® Solution.VIGAMOX® (moxifloxacin hydrochloride ophthalmic solution) 0.5% as baseSterile topical ophthalmic solutionInitial U.S. Approval 1999?

VIGAMOX® solution is contraindicated in patients with a history of hypersensitivity to moxifloxacin, to other quinolones, or to any of the components in this medication.


What might happen if I take too much These highlights do not include all the information needed to use VIGAMOX® Solution safely and effectively. See full prescribing information for VIGAMOX® Solution.VIGAMOX® (moxifloxacin hydrochloride ophthalmic solution) 0.5% as baseSterile topical ophthalmic solutionInitial U.S. Approval 1999?

Sorry No Records found


How should I store and handle These highlights do not include all the information needed to use VIGAMOX® Solution safely and effectively. See full prescribing information for VIGAMOX® Solution.VIGAMOX® (moxifloxacin hydrochloride ophthalmic solution) 0.5% as baseSterile topical ophthalmic solutionInitial U.S. Approval 1999?

StorageStore PROTONIX For Delayed-Release Oral Suspension and PROTONIX Delayed-Release Tablets at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature.] StorageStore PROTONIX For Delayed-Release Oral Suspension and PROTONIX Delayed-Release Tablets at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature.] VIGAMOX® solution is supplied as a sterile ophthalmic solution in Alcon’s DROP-TAINER® dispensing system consisting of a natural low density polyethylene bottle and dispensing plug and tan polypropylene closure. Tamper evidence is provided with a shrink band around the closure and neck area of the package.3 mL in a 4 mL bottle - Storage: Store at 2°C- 25°C (36°F - 77°F).VIGAMOX® solution is supplied as a sterile ophthalmic solution in Alcon’s DROP-TAINER® dispensing system consisting of a natural low density polyethylene bottle and dispensing plug and tan polypropylene closure. Tamper evidence is provided with a shrink band around the closure and neck area of the package.3 mL in a 4 mL bottle - Storage: Store at 2°C- 25°C (36°F - 77°F).VIGAMOX® solution is supplied as a sterile ophthalmic solution in Alcon’s DROP-TAINER® dispensing system consisting of a natural low density polyethylene bottle and dispensing plug and tan polypropylene closure. Tamper evidence is provided with a shrink band around the closure and neck area of the package.3 mL in a 4 mL bottle - Storage: Store at 2°C- 25°C (36°F - 77°F).


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Moxifloxacin is a member of the fluoroquinolone class of anti-infective drugs .

Non-Clinical Toxicology
VIGAMOX® solution is contraindicated in patients with a history of hypersensitivity to moxifloxacin, to other quinolones, or to any of the components in this medication.

Alcohol, Ethyl: Hepatotoxicity has occurred in chronic alcoholics following various dose levels (moderate to excessive) of acetaminophen.

Anticholinergics: The onset of acetaminophen effect may be delayed or decreased slightly, but the ultimate pharmacological effect is not significantly affected by anticholinergics.

Oral Contraceptives: Increase in glucuronidation resulting in increased plasma clearance and a decreased half-life of acetaminophen.

Charcoal (Activated): Reduces acetaminophen absorption when administered as soon as possible after overdose.

Beta Blockers (Propanolol): Propranolol appears to inhibit the enzyme systems responsible for the glucuronidation and oxidation of acetaminophen. Therefore, the pharmacologic effects of acetaminophen may be increased.

Loop Diuretics: The effects of the loop diuretic may be decreased because acetaminophen may decrease renal prostaglandin excretion and decrease plasma renin activity.

Lamotrigine: Serum lamotrigine concentrations may be reduced, producing a decrease in therapeutic effects.

Probenecid: Probenecid may increase the therapeutic effectiveness of acetaminophen slightly.

Zidovudine: The pharmacologic effects of zidovudine may be decreased because of enhanced non-hepatic or renal clearance of zidovudine.

NOT FOR INJECTION. VIGAMOX® solution is for topical ophthalmic use only and should not be injected subconjunctivally or introduced directly into the anterior chamber of the eye.

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The most frequently reported ocular adverse events were conjunctivitis, decreased visual acuity, dry eye, keratitis, ocular discomfort, ocular hyperemia, ocular pain, ocular pruritus, subconjunctival hemorrhage, and tearing. These events occurred in approximately 1-6% of patients.

Nonocular adverse events reported at a rate of 1-4% were fever, increased cough, infection, otitis media, pharyngitis, rash, and rhinitis.

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).